Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
accelerate, accelerated, assessment, Authorisation, biologic, CHMP, Committee, complera, conservative, construct, consultation, Eviplera, foot, Genentech, interferon, introduction, land, month, objective, obsolescence, Oceanside, opinion, peak, pegylated, plant, recommendation, ribavirin, rilpilvirine, seasonality, simplify, square, tangible, therapy, toxicological
Removed:
confirmation, dilution, lease, listing, official, preliminary, protest, restructuring, withhold
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.83 First Amendment to License Agreement
- 10.84 Second Amendment to License Agreement
- 10.85 Third Amendment to License Agreement
- 10.86 Fourth Amendment to License Agreement
- 10.93 Second Amendment to License and Collaboration Agreement
- 31.1 Certification of CEO, As Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification of CFO, As Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certifications of CEO and CFO, As Required by Rule 13A-14(B) or Rule 15D-14(B)
Related press release
GILD similar filings
Filing view
External links